Lv1
60 积分 2025-08-12 加入
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study
19小时前
已完结
Navigating the Evolving Landscape of EGFR -Mutated NSCLC
26天前
已完结
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment
1个月前
已关闭
Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis
1个月前
已完结
Antibody-drug conjugates: new drugs – new toxicities
2个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
3个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
5个月前
已完结
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
5个月前
已完结
皖公网安备34019202002308
